Assessment of safety during hospitalization for patients undergoing Surgery after neoadjuvant therapy for moderately advanced Esophageal cancer

• Published in: BMC surgery 2023-11, Vol.23 (1), p.1-337, Article 337
• Main Authors: Xiong, Chenyi, Ji, Hongyun, Li, Feng, Jiang, Zhihua, Pang, Zhonghao, Li, Xiaoran
• Format: Article
• Language: English
• Subjects: Adjuvant treatment; Anastomotic leak; Blood; Cancer; Cancer patients; Cancer therapies; Care and treatment; Cefonicid; Chemotherapy; Complications; Complications and side effects; Esophageal cancer; Esophageal cancer neoadjuvant therapy security assessment retrospective study; Esophagus; Hemoglobin; Hospitals; Infection; Leukocytes; Lung diseases; Lymph nodes; Lymphatic system; Metastasis; Mortality; Neoadjuvant therapy; Oncology, Experimental; Pathology; Patients; Proteins; Safety; Statistical analysis; Surgery; Surgical anastomosis; Therapy; Thoracic surgery; Thorax; Tumors
• ISSN: 1471-2482; 1471-2482
• DOI: 10.1186/s12893-023-02252-8

Purpose To study the safety of patients with moderately advanced esophageal cancer during their hospital stay after undergoing surgery. Methods The clinical and pathological data of 66 patients with locally advanced esophageal cancer discharged from the Department of Thoracic Surgery of Jiangsu University Hospital from January 2017 to October 2022 were selected, of whom 32 underwent direct surgery (control group) and 34 underwent neoadjuvant therapy followed by surgery (experimental group), to retrospectively analyze whether there were differences in surgical outcomes, complication rates, biochemical and infection indicators between the two groups. Results The number of lymph node dissections, lymph node dissection rate, and hemoglobin value on the first day after the operation in the experimental group were smaller than those in the control group, and the difference was statistically significant (P < 0.05). The thoracic drainage volume of the experimental group was more than that of the control group, and the difference was statistically significant (P < 0.05). The incidence of pulmonary complications in the experimental group was higher than that in the control group, especially pulmonary infection, and the difference was statistically significant (P < 0.05). Compared with the control group, the experimental group was more prone to anastomotic leakage, and the difference was statistically significant (P < 0.05). Conclusion Neoadjuvant therapy combined with surgery for patients with advanced esophageal cancer is generally safe during hospitalization. Keywords: Esophageal cancer neoadjuvant therapy security assessment retrospective study